Sophia Genetics, a specialist in data-driven medicine, has raised $13.75m in its series B. The round was led by Invoke Capital, which was joined by Swisscom and Endeavour Vision.
Apart from the cash injection, Sophia gains access to Invoke’s portfolio company Genalys, which uses big data mathematics to analyse genomic information.
Spun out of the Federal Institute of Technology Lausanne in 2011, the Swiss company’s technology makes it possible to diagnose genetic diseases and the DNA of cancer tumours through a combination of next generation sequencing and highly accurate and scalable predictive algorithms. It is hoped that now that Sophia and Genalys have access to each other’s expertise, the technology can be improved even further.
Sophia Genetics previously raised $2.8m in 2013 from undisclosed investors. The company is ahead of its competition in that it is already fully compliant with European data privacy laws. Its technology is…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?